In the world of brain-computer interfaces (BCIs), China has made a significant move that has sparked both excitement and debate. The country has approved NEO, a brain implant developed by Neuracle Technology, for commercial use in patients with spinal cord injuries. This approval comes before Neuralink's N1 chip, raising questions about the implications and the future of BCI technology.
NEO's unique feature is its placement on the dura mater, the protective membrane covering the brain, rather than directly piercing the cortex. This approach, according to BCI researcher Avinash Singh, presents lower risks of hemorrhage, glial scarring, and long-term signal degradation compared to intracortical devices like Neuralink's N1 chip. However, it comes with a trade-off: signal fidelity. The electrodes on the dura mater collect broader, less precise neural activity, which might not be sufficient for complex applications like speech decoding or fine motor control.
The approved use of NEO is narrow, targeting patients with paralysis in all four limbs from spinal cord injuries who retain some residual arm function. It is not a general movement restoration device and is not approved for speech, vision, or broader motor control. The clinical trial results, though preliminary, show promising outcomes, with a patient recovering the ability to perform grasping movements after BCI-assisted rehabilitation.
The regulatory timing of NEO's approval in China is a result of both engineering and policy factors. The epidural sensor placement reduces the regulatory burden, and China's expedited regulatory pathway, coupled with the incorporation of BCIs into the national health insurance coding system, indicates a strong commitment to the technology. In contrast, the US Food and Drug Administration's approval process typically takes several years longer, reflecting different clinical evidence requirements and priorities in the US.
The comparison between China and the US in BCI development is complex. While China's approach focuses on accessible deployment on a societal scale, the US prioritizes pushing the performance frontier for the highest-resolution neural interfaces. These are not competing paths but different approaches to achieving the same goal.
The collaboration between the US and Chinese BCI industries, despite geopolitical tensions, is an interesting development. Companies like Axoft are conducting trials in China, and the approval of NEO opens up questions about pricing, coverage rates, and the scalability of patient access. The future of BCI technology in both countries remains to be seen, with ongoing research and development pushing the boundaries of what these devices can achieve.
